Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

BACKGROUND: Sintilimab plus chemotherapy significantly prolongs overall survival (OS) for patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC). However, the cost-effectiveness of this high-priced therapy is currently unknown. We evaluated the cost-effectiveness of sintilim...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lulu, Wang, Lei, Chen, Li, Ding, Yiling, Zhang, Qilin, Shu, Yamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899904/
https://www.ncbi.nlm.nih.gov/pubmed/36756110
http://dx.doi.org/10.3389/fimmu.2023.1092385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899904/
https://www.ncbi.nlm.nih.gov/pubmed/36756110
http://dx.doi.org/10.3389/fimmu.2023.1092385

Ejemplares similares